Lung Cancer

Results from a phase 2 trial support the safety and tolerability of VGT-309 in patients with suspected lung cancer who undergo standard-of-care surgical resection.

University of Kansas experts offer guidance for community practitioners treating non-small cell lung cancer (NSCLC).

Dr. Reddy offers expert insights on employing concurrent immunotherapy with chemoradiotherapy, discussing the approach's role and drawing from recent data, such as results from the KEYNOTE-799, PACIFIC-6, and DOLPHIN studies, to inform treatment strategies.

A group of experts in oncology investigates the feasibility of combination adjuvant immunotherapy in NSCLC consolidation, assessing the utilization of multiple immune checkpoint inhibitors and scrutinizing the rationale, with a focus on findings from the COAST study and PACIFIC-8 studies.

Vinay Raja, MD, explores the management of patients with Stage-III disease and actionable EGFR/ALK aberrations, as well as the treatment approach for patients with PD-L1 <1%.

Data from the phase 2 NIPU trial support the FDA’s fast track designation for UV1 in combination with nivolumab and ipilimumab as a treatment for those with unresectable pleural malignant mesothelioma.

A panel of oncology experts examine the role of consolidation immunotherapy in patients receiving concurrent chemoradiotherapy for unresectable Stage-III NSCLC, discussing 5-year survival outcomes from the PACIFIC trial, the impact on institutional treatment approaches, criteria for selecting patients for consolidation durvalumab, the significance of baseline scans, as well as exploring real-world evidence on consolidation durvalumab.

Krishna Reddy, MD, PhD, explores the roles of sequential and concurrent chemoradiotherapy (sCRT and cCRT) in patients with unresectable stage III NSCLC, delving into considerations for selecting between the two approaches and examining potential variations in treatment based on factors such as age, performance status (PS), or comorbidities.

Gregory Gan, MD, briefly outlines the available treatment strategies for stage III unresectable NSCLC, and Alykhan Nagji, MD explores the characterization of patients with unresectable stage III NSCLC, underscoring the crucial role of accurate staging in guiding treatment decisions.

An overview of NRG1 fusion–positive tumors was given by experts in the gastrointestinal and lung cancer space in a recent Frontline Forum.

Misako Nagasaka, MD, PhD, sheds light on neoadjuvant and adjuvant treatment options for patients with lung cancer.

During the European Society for Medical Oncology 2023, experts discussed updated results in key trials across the lung cancer space.

A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Discussion on the treatment for borderline resectable patients with NSCLC.

Alykhan Nagji, MD, provides a brief overview of the landscape surrounding the treatment of patients with stage-III resectable NSCLC.

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.

A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study

The panelists close their discussion on non-small cell lung cancer by emphasizing the need for continued research, early screening, and collaboration with dermatologists to address the unmet needs and improve overall outcomes.

The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.

Highlight on the debate format, speakers, and direction to support the discussion.

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

An outline of the debate, the speakers, and the basic guidelines to support the program.